Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 152,953 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Terminated Phase 2 Interventional Results available

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

NCT02030574
View directory record Official record
Conditions
Invasive Bladder Cancer, Bladder Cancer
Interventions
Gemcitabine and fractionated cisplatin (combination treatment)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 29, 2026, 9:12 PM EDT
Recruiting Phase 1 Interventional

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
Interventions
MQ719, Pembrolizumab
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 9:12 PM EDT
Not listed Phase 4 Interventional

Compression Aided Management of Edema in Patients With C3 Venous Disease

NCT00766974
View directory record Official record
Conditions
Chronic Venous Disease
Interventions
Anti-embolism Knee High Stocking, 20-30 Knee High Compression Stocking
Device
Lead sponsor
BSN Medical Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Roxbury, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2008 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Childcare Outdoor Learning Environments as Active Food Systems

NCT04864574
View directory record Official record
Conditions
Pediatric Obesity, Sedentary Behavior
Interventions
Garden installation
Other
Lead sponsor
North Carolina State University
Other
Eligibility
42 Months to 6 Years
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
15
States / cities
Cary, North Carolina • Fuquay-Varina, North Carolina • Knightdale, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 29, 2026, 9:12 PM EDT
Completed No phase listed Observational

Segmental Bronchoalveolar Lavage

NCT00001618
View directory record Official record
Conditions
Asthma, Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 29, 2026, 9:12 PM EDT
Not listed Phase 2 Interventional

Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease

NCT04258397
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pirfenidone, matching placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 29, 2026, 9:12 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

NCT00096460
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
Interventions
Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
30
States / cities
Duarte, California • La Jolla, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 29, 2026, 9:12 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

NCT00308620
View directory record Official record
Conditions
HIV Infections
Interventions
chloroquine phosphate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 29, 2026, 9:12 PM EDT
Withdrawn Not applicable Interventional

A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia

NCT05663320
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
virtual educational based transition intervention self-paced
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years to 22 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 29, 2026, 9:12 PM EDT
Not listed No phase listed Observational

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

NCT04336020
View directory record Official record
Conditions
Influenza, Virus
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

NCT02524782
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MEDI-4166, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Anniston, Alabama • Chula Vista, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 29, 2026, 9:12 PM EDT
Withdrawn Not applicable Interventional

WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

NCT05032482
View directory record Official record
Conditions
Mild Alzheimer's Disease
Interventions
Non-invasive brainstem stimulation
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
65 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Boca Raton, Florida • Tampa, Florida • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 2 Interventional

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00045682
View directory record Official record
Conditions
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions
Paclitaxel Poliglumex
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 29, 2026, 9:12 PM EDT
Not listed Not applicable Interventional

Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.

NCT06111482
View directory record Official record
Conditions
Dermatologic Conditions
Interventions
Intense pulsed light., Radiofrequency microneedling device, Radiofrequency device, Combined energy devices
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Westford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00109824
View directory record Official record
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
decitabine, valproic acid, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 29, 2026, 9:12 PM EDT
Completed No phase listed Observational

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024
View directory record Official record
Conditions
End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
Interventions
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
View directory record Official record
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 29, 2026, 9:12 PM EDT
Completed No phase listed Observational

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

NCT00471224
View directory record Official record
Conditions
Siderosis
Interventions
Observational Trial
Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 29, 2026, 9:12 PM EDT
Recruiting No phase listed Observational

Augmented Renal Clearance in Neurocritical Care

NCT07410624
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC), Subarachnoid Hemorrhage, Aneurysmal, Ischemic Stroke, Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 85 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 29, 2026, 9:12 PM EDT
Recruiting Phase 2 Interventional

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

NCT05776524
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, TheraBionic
Drug · Device
Lead sponsor
THERABIONIC INC.
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

NCT03618420
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes, Diabetes Mellitus Complication, Autoimmune Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 29, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

NCT01666782
View directory record Official record
Conditions
Cancer, Influenza Viral Infections
Interventions
Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine
Biological
Lead sponsor
Saad Jamshed MD
Other
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 29, 2026, 9:12 PM EDT
Not listed Phase 1 Interventional

Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)

NCT00695682
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration
Interventions
intravitreal injection of infliximab
Drug
Lead sponsor
Retina Research Foundation
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Slingerlands, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2008 · Synced Oct 29, 2026, 9:12 PM EDT